Morphic Therapeutic Shares New Positive MORF-057 Data From IBD Study

Morphic Therapeutic MORF has announced additional data from its Phase 1 trial evaluating MORF-057 for inflammatory bowel disease (IBD).
The data were shared at the Congress of European Crohn's and Colitis Organization 2021 Virtual Congress.
The additional data include detail regarding the safety, pharmacokinetics (PK), and pharmacodynamics (PD) performance of MORF-057 in healthy subjects.
MORF-057 was well tolerated in all cohorts, and no safety signals were identified. It demonstrated a favorable PK profile, and an apparent PK and PD relationship were established.
α4β7 receptor occupancy increased with dose and study day, achieving saturation in patients from all cohorts above 25 mg by day 14.
In the 100 mg BID cohort, MORF-057 saturated the α4β7 receptor (mean RO more than 99%).
Dose-and time-dependent changes in biomarkers, including specific α4β7 high expressing immune cell populations, were observed.
The company held a conference call today at 8:00 AM ET.
Price Action: MORF shares are up 3.16% at $59.43 on the last check Friday.